New EJNMMI paper, showing that tau deposition is related to dopamine difficiency in 4R tauopathies by combining PI-2620 tau-PET and DaT-SPECT. As always, great collaboration and congrats to MatthiasBrendel, @GunterHoglinger and the entire LMU Neurodeg team doi.org/10.1007/s00259…

Out now in The Lancet Neurology A comparison of tau PET pathology in Down Syndrome (DS) and Autosomal Dominant Alzheimer Disease (ADAD). thelancet.com/journals/laneu…

🌊🏄‍♀️ Exciting news! A postdoctoral opportunity is now available in my team in Melbourne! Join us and contribute to cutting-edge research in imaging the aging brain. #postdocopportunity #scienceAustralia 🏖️🐨🦘 jobs.csiro.au/job/Melbourne%…

Don't miss out on the opportunity to join our team! The final day (21st) to apply for this postdoc position is fast approaching. #AlzheimersDisease #NeuroImaging #BrainScience #AlzheimerResearch #Neuroscience #ClinicalTrials #jobopening #careerdevelopment

Are ice cream sales a useful predictor of swimming pool deaths, over and above daily temperature? 🍦🏊‍♂️ One of the statistical papers every PhD student should read! 📊 #Statistics #PhD #Research journals.plos.org/plosone/articl…

Is there clinical evidence for the use of GLP-1 receptor agonists in #Alzheimers disease? Our recent systematic review suggests current data is limited, but upcoming RCT's may yield more insights: content.iospress.com/articles/journ… #ADresearch Vincent Dore Rowe Lab

Not long to go now! Don't forget to register for this unique opportunity to meet Prof Lautenschlager and likeminded researchers in #Neuroscience #Alzheimers hosted by @DrKaramacoska and ISTAART

Latest article from our team in Centre for Precision Health led by #NHMRC Emerging Fellow Dr Emmanuel Adewuyi (Emmanuel Adewuyi). A deep dive into the shared #genetics of type-2 #diabetes & #Gut disorders. Edith Cowan University (ECU) Tenielle Porter Eleanor O'Brien #statisticalgenetics #MR

🚨 NEW PREPRINT! "Prediction of future cognitive decline among cognitively unimpaired individuals using measures of soluble phosphorylated tau or tau tangle pathology" I am very pleased to present our most recent work! It concerns a large multi-cohort study in which we

🚨🚨 Paper alert 🚨 🚨 I am honored to have been part of this article led by Lars Lau Raket. The article provides very important estimations of scenarios for the long-term effect of amyloid-targeting therapies! Also, with Michael Schöll Alexis Moscoso Rial alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

Association of in vivo retention of Flortaucipir PET with tau neuropathology in corresponding brain regions Check out our most recent publication, led by Tove Freiburghaus & Daria Pawlik at Acta Neuropathologica. Main findings: 1⃣ Flortaucipir PET signal primarily reflects tau

Tau PET GWAS turns up potential new #alzheimersdisease gene. The oxidizing enzyme CYP1B1 associates with higher tangle load. IU School of Medicine ow.ly/6YFK50TxvSF

Exciting news! Our findings on the Lumipulse #pTau217 assay were featured in Herald Sun and The Daily Telegraph. In this interview, Prof. Christopher Rowe explains the difference this blood test could make for #Alzheimers diagnosis. Have a read here: dailytelegraph.com.au/news/victoria/…

Approved in Europe the first disease-modifying treatment for #Alzheimer's disease. Great news for patients, families and all of us interested in this devastating disease.

Australians are travelling overseas for dementia treatments like lecanemab after TGA rejection. ADNeT urges approval so that the 433k Australians living with dementia can access the latest treatments at home. #DementiaTreatment #ADNeT ADI

abc.net.au/news/2025-05-2… Finally, some much-needed progress! The TGA in Australia has approved Donanemab for early symptomatic Alzheimer's disease. This offers new hope by slowing cognitive and functional decline. Every step counts! #AlzheimersTreatment #Dementia #Australia

🚨Donanemab has been approved for use in Aus. ADNeT Director Prof Chris Rowe said "Today is a momentous day in the treatment of the most common form of dementia. We must now ensure our health system is ready to bring these new treatments to patients" More➡️buff.ly/EN6SDuV

🚨Donanemab has been approved for use in Aus. ADNeT Director Prof Chris Rowe said "Today is a momentous day in the treatment of the most common form of dementia. We must now ensure our health system is ready to bring these new treatments to patients" More➡️buff.ly/EN6SDuV

After more than 3 years of work, visualizing over 6,500 tau PET scans, and countless manuscript revisions, I still have to blink twice to believe it: our paper “Frequency and Clinical Outcomes Associated With Tau PET Positivity” is now published in JAMA. jamanetwork.com/journals/jama/…

🧪 Les biomarqueurs sont de véritables indices biologiques. Dans la maladie d’Alzheimer, ils permettent de : 🔍 Détecter très tôt la maladie 🧠 Mieux poser le diagnostic 💊 Suivre l’efficacité des traitements 📘 Découvrez notre carrousel de la semaine : fondation-alzheimer.org/biomarqueur/